Mylan gets FDA OK for generic version of Pfizer's allergy drug

Dec 28 (Reuters) - Mylan Inc (MYL.N: Quote, Profile, Research, Stock Buzz) said its Mylan Pharmaceuticals Inc unit received final approval from U.S. health regulators for its generic version of Pfizer Inc's (PFE.N: Quote, Profile, Research, Stock Buzz) allergy drug Zyrtec.

The approval is for Cetirizine Hydrochloride tablets, 5 mg and 10 mg, and the tablets will be shipped immediately, the company said in a statement.

Zyrtec had U.S. sales of about $1.4 billion for the 12 months ended Sept. 30. (Reporting by Purwa Khandelwal in Bangalore; Editing by Gopakumar Warrier)